发布求助
文献互助 智能选刊 最新文献

Leukemia Research Reports最新文献

筛选
英文 中文
Targeting menin for precision therapy in high-risk acute myeloid leukemia 以 Menin 为靶点，对高风险急性髓性白血病进行精准治疗。
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100495
Abdur Jamil , Zaheer Qureshi , Zain Mary El-amir , Gillian Kupakuwana-Suk , Hamzah Akram , Mohsin Ahmad , Eric Huselton
{"title":"Targeting menin for precision therapy in high-risk acute myeloid leukemia","authors":"Abdur Jamil ,&nbsp;Zaheer Qureshi ,&nbsp;Zain Mary El-amir ,&nbsp;Gillian Kupakuwana-Suk ,&nbsp;Hamzah Akram ,&nbsp;Mohsin Ahmad ,&nbsp;Eric Huselton","doi":"10.1016/j.lrr.2024.100495","DOIUrl":"10.1016/j.lrr.2024.100495","url":null,"abstract":"<div><h3>Objective</h3><div>This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways.</div></div><div><h3>Summary</h3><div>The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100495"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML 病例报告：flt3阳性AML患者急性胰腺炎后再用吉替尼治疗
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100503
Taner TAN , Genco Gençdal , Ümit Barbaros Üre , Olga Meltem AKAY
{"title":"Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML","authors":"Taner TAN ,&nbsp;Genco Gençdal ,&nbsp;Ümit Barbaros Üre ,&nbsp;Olga Meltem AKAY","doi":"10.1016/j.lrr.2025.100503","DOIUrl":"10.1016/j.lrr.2025.100503","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100503"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thymic stromal lymphopoietin in leukemia: A double-edged sword? 胸腺基质淋巴生成素治疗白血病：一把双刃剑？
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100530
Xing Zou , Mengmeng Gu , Yue Su , Dayong Yao , Hao Gang , Yang Li , Ce Shi
{"title":"Thymic stromal lymphopoietin in leukemia: A double-edged sword?","authors":"Xing Zou ,&nbsp;Mengmeng Gu ,&nbsp;Yue Su ,&nbsp;Dayong Yao ,&nbsp;Hao Gang ,&nbsp;Yang Li ,&nbsp;Ce Shi","doi":"10.1016/j.lrr.2025.100530","DOIUrl":"10.1016/j.lrr.2025.100530","url":null,"abstract":"<div><div>Thymic stromal lymphopoietin (TSLP) is a cytokine expressed by various cell types. It is involved in the development of allergies, autoimmune diseases, and cancers. TSLP affects immune responses and disease pathogenesis by binding to a heterodimeric receptor complex. In leukemia, particularly acute lymphoblastic leukemia (ALL), the importance of TSLP is being increasingly recognized. It has been shown that TSLP promotes leukemia proliferation by regulating different signaling pathways. However, it has also shown that other gene mutations can occur during this proliferative process, making it impossible to completely cure leukemia by targeting TSLP alone. Additionally, effect of TSLP on leukemia was found to be dose dependent. Whilst low doses were found to support the proliferation of leukemia cells, high doses were found to induce apoptosis in leukemia cells. This review focuses on the dual mechanisms of TSLP in leukemia, providing new insights for leukemia treatment.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100530"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report 慢性髓单细胞白血病合并罕见抗体患者的溶血性输血反应的处理：1例报告
IF 0.7
Leukemia Research Reports Pub Date : 2024-11-28 DOI: 10.1016/j.lrr.2024.100485
Grace S. Park , Himachandana Atluri , Courtney D. DiNardo , Bryan Guillroy , Jean Horak , Effrosyni Apostolidou , Maryam Buni , Guillermo Montalban Bravo , Naveen Pemmaraju
{"title":"Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report","authors":"Grace S. Park ,&nbsp;Himachandana Atluri ,&nbsp;Courtney D. DiNardo ,&nbsp;Bryan Guillroy ,&nbsp;Jean Horak ,&nbsp;Effrosyni Apostolidou ,&nbsp;Maryam Buni ,&nbsp;Guillermo Montalban Bravo ,&nbsp;Naveen Pemmaraju","doi":"10.1016/j.lrr.2024.100485","DOIUrl":"10.1016/j.lrr.2024.100485","url":null,"abstract":"<div><div>Delayed hemolytic transfusion reaction (DHTR) poses a significant challenge in patients receiving blood transfusions. This case report highlights the complexities of managing DHTR in a newly diagnosed chronic myelomonocytic leukemia (CMML) patient with clinically significant JKa and little c antibodies during induction chemotherapy. A 46-year-old woman with CMML-2 who presented for induction chemotherapy was found to have hemolytic anemia. Due to presence of JKa and little c antibodies, she required intensive monitoring and supportive care measures. The coexistence of JKa and little c antibodies complicates transfusion management and chemotherapy tolerance in CMML patients.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100485"},"PeriodicalIF":0.7,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute lower limb ischemia revealing hypo granular acute promyelocytic leukemia 急性下肢缺血显示低颗粒急性早幼粒细胞白血病
IF 0.7
Leukemia Research Reports Pub Date : 2024-11-25 DOI: 10.1016/j.lrr.2024.100488
Sabrina Belmahi , Zainab Kajeiou , Loubna Yacoubi , Noussaiba Azzi , Mounia Slaoui , Abdelilah Berhili , Mohammed Bensalah , Rachid Seddik
{"title":"Acute lower limb ischemia revealing hypo granular acute promyelocytic leukemia","authors":"Sabrina Belmahi ,&nbsp;Zainab Kajeiou ,&nbsp;Loubna Yacoubi ,&nbsp;Noussaiba Azzi ,&nbsp;Mounia Slaoui ,&nbsp;Abdelilah Berhili ,&nbsp;Mohammed Bensalah ,&nbsp;Rachid Seddik","doi":"10.1016/j.lrr.2024.100488","DOIUrl":"10.1016/j.lrr.2024.100488","url":null,"abstract":"<div><h3>Introduction</h3><div>Acute promyelocytic leukemia (AML-M3), classified as acute Myeloid leukemia with PML RARA according to the 5th edition of the World Health Organization classification of haematolymphoid tumors 2022 [1], is marked by abnormal promyelocyte proliferation and is known for high risks of bleeding and thromboembolic complications. We present a case where lower limb ischemia revealed this leukemia in a child.</div></div><div><h3>Case report</h3><div>An 11-year-old with minor ankle trauma developed severe lower limb ischemia, leading to the discovery of subtotal femoral artery thrombosis. Blood tests revealed hyperleukocytosis, thrombocytopenia, and anemia with 88 % blasts, confirming acute myeloid leukemia (AML-M3). Karyotyping showed a t(15;17) translocation, and the child was started on emergency chemotherapy.</div></div><div><h3>Discussion</h3><div>Acute promyelocytic leukemia (APL), classified as AML-M3 with PML-RARA, is characterized by abnormal promyelocytes and accounts for about 10 % of acute leukemias, mostly in middle-aged adults. It has two variants: common hypergranular and rare hypogranular forms. APL can present with bone marrow failure, anemia, bleeding, and occasionally thromboembolic events, as seen in this case. The ischemia mechanism is not fully understood but may involve vessel obstruction by blasts or hypercoagulability. Diagnosis relies on clinical, morphological, phenotypic, and cytogenetic evidence, with treatment involving all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).</div></div><div><h3>Conclusion</h3><div>Hypogranular acute promyelocytic leukemia (AML3v) is a rare form and is even rarer when it is discovered following an ischaemic event, which is what makes our case so special.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100488"},"PeriodicalIF":0.7,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country 越南骨髓增生异常肿瘤患者的治疗：在发展中国家的实践经验
IF 0.7
Leukemia Research Reports Pub Date : 2024-11-24 DOI: 10.1016/j.lrr.2024.100490
Quang Hao Nguyen , Minh Phuong Vu , Ha Trang Kieu , Duc Binh Vu , Ha Thanh Nguyen , Quoc Khanh Bach
{"title":"Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country","authors":"Quang Hao Nguyen ,&nbsp;Minh Phuong Vu ,&nbsp;Ha Trang Kieu ,&nbsp;Duc Binh Vu ,&nbsp;Ha Thanh Nguyen ,&nbsp;Quoc Khanh Bach","doi":"10.1016/j.lrr.2024.100490","DOIUrl":"10.1016/j.lrr.2024.100490","url":null,"abstract":"<div><h3>Background</h3><div>Treatment of patients diagnosed with myelodysplastic neoplasms (MDS) is difficult and the outcome is still limited, especially in developing countries. We conducted this study in order to share some experience in treating patients diagnosed with MDS in developing countries.</div></div><div><h3>Methods</h3><div>This was a retrospective study that included 32 patients with newly MDS. 13 lower-risk patients, including 2 patients with MDS 5q- were treated with erythropoiesis stimulating agent (ESA). 19 patients with higher risk were treated with hypomethylating agent (HMA), which was decitabine.</div></div><div><h3>Results</h3><div>In the ESA treatment group, the rate of hematologic improvement-erythroid was 69.2 %, the rate of total hematologic improvement (with 3 lineages improvement) was 61.5 %. In the HMA treatment group, the overall response rate was 52.6 %. The follow-up times were 42 months. The overall survival (OS), leukemic transformation-free survival (LFS), and progression-free survival (PFS) of the ESA treatment group were 30.44, 28.91, and 28.29 months; respectively. The OS, LFS, and PFS of the HMA treatment group were 34.27, 31.45, and 26.83 months; respectively<strong>.</strong></div></div><div><h3>Conclusions</h3><div>Patients with lower risk MDS, including MDS 5q-, may benefit from treatment with erythropoiesis stimulating agent (ESA). Patients with higher risk MDS may have a favorable outcome with decitabine (HMA) treatment.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100490"},"PeriodicalIF":0.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Septic arthritis as breakthrough invasive fusariosis after cord blood transplantation 脐带血移植后作为突破性侵袭性镰刀菌病的化脓性关节炎
IF 0.7
Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100483
Shinichi Katsuoka , Hidehiro Itonaga , Yasushi Sawayama , Masahiko Chiwata , Haruka Watanabe , Yuichi Yamada , Machiko Fujioka , Takeharu Kato , Shinya Sato , Koji Ando , Masato Tashiro , Takahiro Takazono , Yoshitaka Imaizumi , Koichi Izumikawa , Katsunori Yanagihara , Hiroshi Mukae , Yasushi Miyazaki
{"title":"Septic arthritis as breakthrough invasive fusariosis after cord blood transplantation","authors":"Shinichi Katsuoka ,&nbsp;Hidehiro Itonaga ,&nbsp;Yasushi Sawayama ,&nbsp;Masahiko Chiwata ,&nbsp;Haruka Watanabe ,&nbsp;Yuichi Yamada ,&nbsp;Machiko Fujioka ,&nbsp;Takeharu Kato ,&nbsp;Shinya Sato ,&nbsp;Koji Ando ,&nbsp;Masato Tashiro ,&nbsp;Takahiro Takazono ,&nbsp;Yoshitaka Imaizumi ,&nbsp;Koichi Izumikawa ,&nbsp;Katsunori Yanagihara ,&nbsp;Hiroshi Mukae ,&nbsp;Yasushi Miyazaki","doi":"10.1016/j.lrr.2024.100483","DOIUrl":"10.1016/j.lrr.2024.100483","url":null,"abstract":"<div><div>A 63-year-old male received a third allogeneic hematopoietic stem cell transplantation with voriconazole prophylaxis for relapsed acute myeloid leukemia. He developed septic arthritis without any typical skin lesions due to fungal infection on day 42. Treatment with liposomal amphotericin B was initiated following surgical debridement; however, he died of progressive fungal infection. Ribosomal DNA sequencing identified <em>Fusarium solani</em> species complex (FSSC) harboring voriconazole resistance. This clinical course indicates that breakthrough invasive fusariosis (azole-resistant FSSC infection) needs to be considered as a pathogen when patients with hematological malignancies develop septic arthritis without typical skin lesions during voriconazole prophylaxis.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100483"},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients 治疗耶和华见证人患者中的费城染色体阳性急性淋巴细胞白血病
IF 0.7
Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100474
Jeffrey Baron , Manu R. Pandey , Elizabeth A. Griffiths , Eunice S. Wang
{"title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients","authors":"Jeffrey Baron ,&nbsp;Manu R. Pandey ,&nbsp;Elizabeth A. Griffiths ,&nbsp;Eunice S. Wang","doi":"10.1016/j.lrr.2024.100474","DOIUrl":"10.1016/j.lrr.2024.100474","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100474"},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000645/pdfft?md5=3040d4d2694de947d12371d548eb36f2&pid=1-s2.0-S2213048924000645-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic myeloid leukemia with involvement of membranous labyrinth 慢性髓性白血病累及膜迷路
IF 0.7
Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100471
Mobachir El Kettani , Kashish Shah , Hareem Farooq , Ke Li , Talha Badar
{"title":"Chronic myeloid leukemia with involvement of membranous labyrinth","authors":"Mobachir El Kettani ,&nbsp;Kashish Shah ,&nbsp;Hareem Farooq ,&nbsp;Ke Li ,&nbsp;Talha Badar","doi":"10.1016/j.lrr.2024.100471","DOIUrl":"10.1016/j.lrr.2024.100471","url":null,"abstract":"<div><p>This case report explains an extraordinary presentation of chronic myeloid leukemia (CML) in a 39-year-old male with a T315I mutation, presenting with acute bilateral hearing loss and imbalance secondary to myeloid blast crisis. Neurological involvement was confirmed through MRI brain and cerebrospinal fluid analysis. Initial treatment with ponatinib and FLAG (fludarabine, cytarabine, G-CSF) regimen showed promise, but complications necessitated discontinuation. The patient's complex clinical trajectory, marked by complications and intolerance to tyrosine kinase inhibitors, highlights the intricate nature of CML blast crisis with T315I mutation management. Recognizing atypical presentations and early mutation analysis are pivotal for tailored treatment strategies.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100471"},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221304892400061X/pdfft?md5=72e11a1ea336e7231d57c0f3856bed99&pid=1-s2.0-S221304892400061X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world treatments and clinical outcomes in unfit AML patients receiving first-line treatment or best supportive care in Italy (CURRENT study) 意大利接受一线治疗或最佳支持治疗的不适合急性髓细胞白血病患者的实际治疗情况和临床结果（CURRENT 研究）
Leukemia Research Reports Pub Date : 2024-01-01 DOI: 10.1016/j.lrr.2024.100453
Maria Paola Martelli , Nicola Di Renzo , Antonio Curti , Nicola Stefano Fracchiolla , Luca Maurillo , Morena Caira , Paola Finsinger , Giuliana Gualberti , Felicetto Ferrara , Attilio Olivieri
{"title":"Real-world treatments and clinical outcomes in unfit AML patients receiving first-line treatment or best supportive care in Italy (CURRENT study)","authors":"Maria Paola Martelli ,&nbsp;Nicola Di Renzo ,&nbsp;Antonio Curti ,&nbsp;Nicola Stefano Fracchiolla ,&nbsp;Luca Maurillo ,&nbsp;Morena Caira ,&nbsp;Paola Finsinger ,&nbsp;Giuliana Gualberti ,&nbsp;Felicetto Ferrara ,&nbsp;Attilio Olivieri","doi":"10.1016/j.lrr.2024.100453","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100453","url":null,"abstract":"<div><p>Real-world data on treatment patterns and outcomes of patients with acute myeloid leukemia unfit for intensive chemotherapy are lacking before the advent of precision medicine in this setting.</p><p>Herein, we present the Italian sub-analysis of the CURRENT study in AML patients unfit for first line intensive chemotherapy, evaluating patients’ outcomes between 2015 and 2018.</p><p>Among 74 evaluable patients, 62 received systemic treatments (most used therapy was hypomethylating agents), while 12 best supportive care.</p><p>Key results include both efficacy and safety data, as well as HCRU and treatment patterns. In first-line therapy cohort median OS was 13.4 months vs. 2.7 months for BSC.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100453"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000438/pdfft?md5=f5c1ed3740748c30eca95f71c3a15eda&pid=1-s2.0-S2213048924000438-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140063297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信